{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T01:02:22Z","timestamp":1794186142498,"version":"4.8.0"},"reference-count":89,"publisher":"BMJ","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2024,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effectiveness of three commonly prescribed oral antidiabetic drugs added to metformin for people with type 2 diabetes mellitus requiring second line treatment in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cohort study emulating a comparative effectiveness trial (target trial).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Linked primary care, hospital, and death data in England, 2015-21.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>75\u2009739 adults with type 2 diabetes mellitus who initiated second line oral antidiabetic treatment with a sulfonylurea, DPP-4 inhibitor, or SGLT-2 inhibitor added to metformin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>\n                      Primary outcome was absolute change in glycated haemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ) between baseline and one year follow-up. Secondary outcomes were change in body mass index (BMI), systolic blood pressure, and estimated glomerular filtration rate (eGFR) at one year and two years, change in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      at two years, and time to \u226540% decline in eGFR, major adverse kidney event, hospital admission for heart failure, major adverse cardiovascular event (MACE), and all cause mortality. Instrumental variable analysis was used to reduce the risk of confounding due to unobserved baseline measures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      75\u2009739 people initiated second line oral antidiabetic treatment with sulfonylureas (n=25\u2009693, 33.9%), DPP-4 inhibitors (n=34\u2009464 ,45.5%), or SGLT-2 inhibitors (n=15\u2009582, 20.6%). SGLT-2 inhibitors were more effective than DPP-4 inhibitors or sulfonylureas in reducing mean HbA\n                      <jats:sub>1c<\/jats:sub>\n                      values between baseline and one year. After the instrumental variable analysis, the mean differences in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      change between baseline and one year were \u22122.5 mmol\/mol (95% confidence interval (CI) \u22123.7 to \u22121.3) for SGLT-2 inhibitors versus sulfonylureas and \u22123.2 mmol\/mol (\u22124.6 to \u22121.8) for SGLT-2 inhibitors versus DPP-4 inhibitors. SGLT-2 inhibitors were more effective than sulfonylureas or DPP-4 inhibitors in reducing BMI and systolic blood pressure. For some secondary endpoints, evidence for SGLT-2 inhibitors being more effective was lacking\u2014the hazard ratio for MACE, for example, was 0.99 (95% CI 0.61 to 1.62) versus sulfonylureas and 0.91 (0.51 to 1.63) versus DPP-4 inhibitors. SGLT-2 inhibitors had reduced hazards of hospital admission for heart failure compared with DPP-4 inhibitors (0.32, 0.12 to 0.90) and sulfonylureas (0.46, 0.20 to 1.05). The hazard ratio for a \u226540% decline in eGFR indicated a protective effect versus sulfonylureas (0.42, 0.22 to 0.82), with high uncertainty in the estimated hazard ratio versus DPP-4 inhibitors (0.64, 0.29 to 1.43).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This emulation study of a target trial found that SGLT-2 inhibitors were more effective than sulfonylureas or DPP-4 inhibitors in lowering mean HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , BMI, and systolic blood pressure and in reducing the hazards of hospital admission for heart failure (\n                      <jats:italic>v<\/jats:italic>\n                      DPP-4 inhibitors) and kidney disease progression (\n                      <jats:italic>v<\/jats:italic>\n                      sulfonylureas), with no evidence of differences in other clinical endpoints.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2023-077097","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T10:30:44Z","timestamp":1715164244000},"page":"e077097","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data"],"prefix":"10.1136","volume":"385","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7644-2030","authenticated-orcid":false,"given":"Patrick","family":"Bidulka","sequence":"first","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Lugo-Palacios","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlagh","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda I","family":"Adler","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Headington, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Basu","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Silverwood","sequence":"additional","affiliation":[{"name":"Centre for Longitudinal Studies, UCL Social Research Institute, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Nitsch","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Charlton","sequence":"additional","affiliation":[{"name":"Patient author, Patient Research Champion Team, National Institute for Health and Care Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Briggs","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Smeeth","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J","family":"Douglas","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grieve","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"2025110102325317000_385.may08_8.e077097.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"2025110102325317000_385.may08_8.e077097.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.4310"},{"key":"2025110102325317000_385.may08_8.e077097.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025110102325317000_385.may08_8.e077097.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5887"},{"key":"2025110102325317000_385.may08_8.e077097.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S006"},{"key":"2025110102325317000_385.may08_8.e077097.6","unstructured":"National Institute for Health and Care Excellence. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. Technology appraisal guidance TA390. NICE, 2016. https:\/\/www.nice.org.uk\/guidance\/ta390."},{"key":"2025110102325317000_385.may08_8.e077097.7","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline NG28. NICE, 2022. https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Recommendations#reviewing-drug-treatments."},{"key":"2025110102325317000_385.may08_8.e077097.8","unstructured":"Scottish Intercollegiate Guidelines Network . SIGN 154: Pharmacological management of glycaemic control in people with type 2 diabetes. SIGN, 2017. https:\/\/www.sign.ac.uk\/our-guidelines\/pharmacological-management-of-glycaemic-control-in-people-with-type-2-diabetes\/."},{"key":"2025110102325317000_385.may08_8.e077097.9","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"2025110102325317000_385.may08_8.e077097.10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14400"},{"key":"2025110102325317000_385.may08_8.e077097.11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14874"},{"key":"2025110102325317000_385.may08_8.e077097.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022768"},{"key":"2025110102325317000_385.may08_8.e077097.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.12.015"},{"key":"2025110102325317000_385.may08_8.e077097.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577"},{"key":"2025110102325317000_385.may08_8.e077097.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"2025110102325317000_385.may08_8.e077097.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2025110102325317000_385.may08_8.e077097.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"2025110102325317000_385.may08_8.e077097.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"2025110102325317000_385.may08_8.e077097.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967"},{"key":"2025110102325317000_385.may08_8.e077097.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"2025110102325317000_385.may08_8.e077097.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"2025110102325317000_385.may08_8.e077097.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2025110102325317000_385.may08_8.e077097.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2025110102325317000_385.may08_8.e077097.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2025110102325317000_385.may08_8.e077097.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269"},{"key":"2025110102325317000_385.may08_8.e077097.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"2025110102325317000_385.may08_8.e077097.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00994.x"},{"key":"2025110102325317000_385.may08_8.e077097.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00704.x"},{"key":"2025110102325317000_385.may08_8.e077097.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200433"},{"key":"2025110102325317000_385.may08_8.e077097.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.13772"},{"key":"2025110102325317000_385.may08_8.e077097.31","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2762"},{"key":"2025110102325317000_385.may08_8.e077097.32","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.6664"},{"key":"2025110102325317000_385.may08_8.e077097.33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13970"},{"key":"2025110102325317000_385.may08_8.e077097.34","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01345-z"},{"key":"2025110102325317000_385.may08_8.e077097.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070717"},{"key":"2025110102325317000_385.may08_8.e077097.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200436"},{"key":"2025110102325317000_385.may08_8.e077097.37","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.1487"},{"key":"2025110102325317000_385.may08_8.e077097.38","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6128"},{"key":"2025110102325317000_385.may08_8.e077097.39","doi-asserted-by":"publisher","DOI":"10.2202\/1557-4679.1072"},{"key":"2025110102325317000_385.may08_8.e077097.40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00171-7"},{"key":"2025110102325317000_385.may08_8.e077097.41","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2025110102325317000_385.may08_8.e077097.42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046912"},{"key":"2025110102325317000_385.may08_8.e077097.43","unstructured":"Bidulka P, Lugo-Palacios DG, Carroll O, O\u2019Neill S, Grieve R. Statistical Analysis Plan (SAP): PERsonalised Medicine for Intensification of Treatment (PERMIT) study, Version 1.0, July 2023. https:\/\/www.lshtm.ac.uk\/media\/72276."},{"key":"2025110102325317000_385.may08_8.e077097.44","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025110102325317000_385.may08_8.e077097.45","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2025110102325317000_385.may08_8.e077097.46","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx015"},{"key":"2025110102325317000_385.may08_8.e077097.47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2350"},{"key":"2025110102325317000_385.may08_8.e077097.48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057909"},{"key":"2025110102325317000_385.may08_8.e077097.49","unstructured":"Linked HES-ONS mortality data. NHS Digital; 2020. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/linked-hes-ons-mortality-data#ons-mortality-data."},{"key":"2025110102325317000_385.may08_8.e077097.50","unstructured":"Penney B. The English Indices of Deprivation 2019. 2019."},{"key":"2025110102325317000_385.may08_8.e077097.51","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S176142"},{"key":"2025110102325317000_385.may08_8.e077097.52","unstructured":"NHS England - About Us - Regional Teams. NHS England. https:\/\/www.england.nhs.uk\/about\/regional-area-teams\/."},{"key":"2025110102325317000_385.may08_8.e077097.53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003389"},{"key":"2025110102325317000_385.may08_8.e077097.54","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.030"},{"key":"2025110102325317000_385.may08_8.e077097.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.07.013"},{"key":"2025110102325317000_385.may08_8.e077097.56","doi-asserted-by":"publisher","DOI":"10.2307\/2171753"},{"key":"2025110102325317000_385.may08_8.e077097.57","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4719"},{"key":"2025110102325317000_385.may08_8.e077097.58","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000279"},{"key":"2025110102325317000_385.may08_8.e077097.59","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0262.00277"},{"key":"2025110102325317000_385.may08_8.e077097.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2007.09.009"},{"key":"2025110102325317000_385.may08_8.e077097.61","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3647"},{"key":"2025110102325317000_385.may08_8.e077097.62","doi-asserted-by":"publisher","DOI":"10.2307\/1269656"},{"key":"2025110102325317000_385.may08_8.e077097.63","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x"},{"key":"2025110102325317000_385.may08_8.e077097.64","doi-asserted-by":"publisher","DOI":"10.3982\/ECTA9626"},{"key":"2025110102325317000_385.may08_8.e077097.65","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696"},{"key":"2025110102325317000_385.may08_8.e077097.66","unstructured":"van Buuren S, Oudshoorn CGM. Multivariate Imputation by Chained Equations: MICE V1.0 User\u2019s manual. TNO Report PG\/VGZ\/00.038. Leiden, Netherlands; 2000."},{"key":"2025110102325317000_385.may08_8.e077097.67","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-237"},{"key":"2025110102325317000_385.may08_8.e077097.68","doi-asserted-by":"publisher","DOI":"10.1080\/13645579.2015.1126486"},{"key":"2025110102325317000_385.may08_8.e077097.69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-75"},{"key":"2025110102325317000_385.may08_8.e077097.70","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3618"},{"key":"2025110102325317000_385.may08_8.e077097.71","doi-asserted-by":"publisher","DOI":"10.1177\/0962280220932189"},{"key":"2025110102325317000_385.may08_8.e077097.72","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7654"},{"key":"2025110102325317000_385.may08_8.e077097.73","unstructured":"Therneau T. A Package for Survival Analysis in R: R package version 3.4-0, 2022. https:\/\/CRAN.R-project.org\/package=survival."},{"key":"2025110102325317000_385.may08_8.e077097.74","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i03"},{"key":"2025110102325317000_385.may08_8.e077097.75","unstructured":"Team RCR . A language and environment for statistical computing. R Foundation for Statistical Computing, 2022, https:\/\/www.R-project.org\/."},{"key":"2025110102325317000_385.may08_8.e077097.76","unstructured":"StataCorp . Stata Statistical Software: Release 17 College Station. StataCorp LLC, 2021."},{"key":"2025110102325317000_385.may08_8.e077097.77","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5657"},{"key":"2025110102325317000_385.may08_8.e077097.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeconom.2007.02.002"},{"key":"2025110102325317000_385.may08_8.e077097.79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"2025110102325317000_385.may08_8.e077097.80","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab041"},{"key":"2025110102325317000_385.may08_8.e077097.81","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq198"},{"key":"2025110102325317000_385.may08_8.e077097.82","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq439"},{"key":"2025110102325317000_385.may08_8.e077097.83","unstructured":"PERMIT. Investigating the effectiveness of different treatments for Type 2 Diabetes Mellitus, to help choose the right treatments for patients. London School of Hygiene and Tropical Medicine, 2023. https:\/\/www.lshtm.ac.uk\/research\/centres-projects-groups\/permit#welcome."},{"key":"2025110102325317000_385.may08_8.e077097.84","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36023"},{"key":"2025110102325317000_385.may08_8.e077097.85","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4221"},{"key":"2025110102325317000_385.may08_8.e077097.86","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes [B] Pharmacological therapies with cardiovascular and other benefits in people with type 2 diabetes, NICE guideline NG28. NICE, 2022. https:\/\/www.nice.org.uk\/guidance\/ng28\/evidence\/b-pharmacological-therapies-with-cardiovascular-and-other-benefits-in-people-with-type-2-diabetes-pdf-10956473392."},{"key":"2025110102325317000_385.may08_8.e077097.87","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14780"},{"key":"2025110102325317000_385.may08_8.e077097.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.085"},{"key":"2025110102325317000_385.may08_8.e077097.89","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01071-y"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2023-077097","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2023-077097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:32:59Z","timestamp":1761989579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2023-077097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":89,"alternative-id":["10.1136\/bmj-2023-077097"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2023-077097","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]}}}